Collaboration Details

Print  Close

Title of Collaborative Activity:

Extracting Adverse Reactions and Indexing the Content of Structured Product Labels (SPLs)

Description of Collaborative Activity:

The objective of this initiative is for NLM to assist the U.S. Food and Drug Administration (FDA) in indexing the content of structured product labels (SPL) for drugs. Natural language processing technology is used to extract drug-drug interaction information from SPLs which will be validated by FDA subject matter experts. Transforming the narrative text to structured information encoded in national standard terminologies is a prerequisite to the effective deployment of drug safety information in drug labels for clinical decision support. Starting in FY16, LHC and FDA/CDER collaborate on advancing automated extraction of Adverse Reactions (ARs) from drug listing information companies have submitted to FDA in the form of Structured Product Labels (SPLs). The goals of the initial agreement were to develop optimal MetaMap settings for extracting ARs from SPLs and provide FDA with the software necessary to replicate the results. To evaluate the extraction quality, LHC and FDA needed to develop a test collection of SPLs annotated with ARs. Working together, LHC and FDA have developed annotation guidelines. LHC have annotated 200 SPLs and coded the results to MedDRA, the official controlled vocabulary used by FDA to normalize the labeled ARs. In FY17, the collaboration continues with the goals to conduct a community wide evaluation of the available AR extraction tools. The evaluation venue is NIST Text Analysis Conference (TAC).

Type of Collaborative Activity:

Resource Development

Year the Collaborative Activity Originated:


NIH Participating Institutes/Centers/Office of the Director:


HHS Agency Collaborators on this Activity: